Sepp-Lorenzino Laura
SEC CIK 1777421 · EDGAR
BoughtSold
Most active insiders at TSHA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Nagendran Sukumar | Pres, Head of R, D, Dir | — | $5.33M |
| 2 | Nolan Sean P. | CEO, Dir | — | $840.2K |
| 3 | Alam Kamran | CFO | — | $492.5K |
| 4 | Long Alison S | Dir | — | — |
| 5 | Sepp-Lorenzino Laura | Dir | — | — |
| 6 | Stalfort John A III | Dir | — | — |
| 7 | Donenberg Phillip B. | Dir | — | — |
Transactions 19
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-06-02 16:30 | 2026-06-01 | TSHA | Taysha Gene Therapies, Inc. | Sepp-Lorenzino Laura | Dir | A - Grant | $0.00 | +21.3K | 127.2K | +20% | $0 |
| D | 2025-06-04 | 2025-06-02 | TSHA | Taysha Gene Therapies, Inc. | Sepp-Lorenzino Laura | Dir | A - Grant | $0.00 | +56.6K | 105.8K | +115% | $0 |
| 2025-01-07 | 2025-01-03 | NTLA | Intellia Therapeutics, Inc. | Sepp-Lorenzino Laura | EVP, CSO | S - Sale | $12.18 | -8,966 | 77.4K | -10% | -$109.2K | |
| D | 2025-01-03 | 2025-01-01 | NTLA | Intellia Therapeutics, Inc. | Sepp-Lorenzino Laura | EVP, CSO | M - OptEx | — | +3,500 | 86.4K | +4% | — |
| D | 2024-05-31 | 2024-05-29 | TSHA | Taysha Gene Therapies, Inc. | Sepp-Lorenzino Laura | Dir | A - Grant | $0.00 | +49.2K | 49.2K | New | $0 |
| D | 2024-03-05 | 2024-03-01 | NTLA | Intellia Therapeutics, Inc. | Sepp-Lorenzino Laura | EVP, CSO | A - Grant | $0.00 | +38.0K | 81.9K | +86% | $0 |
| MT | 2024-01-10 | 2024-01-08 | NTLA | Intellia Therapeutics, Inc. | Sepp-Lorenzino Laura | EVP, CSO | S - Sale | $28.87 | -2,275 | 44.6K | -5% | -$65.7K |
| 2024-01-05 | 2024-01-03 | NTLA | Intellia Therapeutics, Inc. | Sepp-Lorenzino Laura | EVP, CSO | S - Sale | $29.46 | -5,532 | 46.2K | -11% | -$163.0K | |
| D | 2024-01-03 | 2024-01-01 | NTLA | Intellia Therapeutics, Inc. | Sepp-Lorenzino Laura | EVP, CSO | M - OptEx | — | +3,500 | 51.7K | +7% | — |
| D | 2023-03-03 | 2023-03-01 | NTLA | Intellia Therapeutics, Inc. | Sepp-Lorenzino Laura | EVP, CSO | A - Grant | $0.00 | +29.9K | 47.6K | +170% | $0 |
| M | 2023-01-06 | 2023-01-04+ | NTLA | Intellia Therapeutics, Inc. | Sepp-Lorenzino Laura | EVP, CSO | S - Sale | $37.82 | -4,838 | 17.6K | -22% | -$183.0K |
| D | 2023-01-04 | 2023-01-01 | NTLA | Intellia Therapeutics, Inc. | Sepp-Lorenzino Laura | EVP, CSO | M - OptEx | — | +3,500 | 22.5K | +18% | — |
| D | 2022-03-03 | 2022-03-01 | NTLA | Intellia Therapeutics, Inc. | Sepp-Lorenzino Laura | EVP, CSO | A - Grant | $0.00 | +13.8K | 18.6K | +287% | $0 |
| D | 2022-03-03 | 2022-01-01 | NTLA | Intellia Therapeutics, Inc. | Sepp-Lorenzino Laura | EVP, CSO | S - Sale+OE | $112.25 | -1,148 | 4,815 | -19% | -$128.9K |
| D | 2022-03-03 | 2022-01-01 | NTLA | Intellia Therapeutics, Inc. | Sepp-Lorenzino Laura | EVP, CSO | M - OptEx | — | +3,500 | 5,963 | +142% | — |
| DM | 2021-09-01 | 2021-08-30 | NTLA | Intellia Therapeutics, Inc. | Sepp-Lorenzino Laura | EVP, CSO | M - OptEx | $14.01 | +97.0K | 99.4K | +4,057% | +$1.36M |
| DM | 2021-09-01 | 2021-08-30 | NTLA | Intellia Therapeutics, Inc. | Sepp-Lorenzino Laura | EVP, CSO | S - Sale+OE | $154.83 | -97.0K | 6,766 | -93% | -$15.02M |
| DM | 2021-08-06 | 2021-08-04 | NTLA | Intellia Therapeutics, Inc. | Sepp-Lorenzino Laura | EVP, CSO | S - Sale+OE | $138.24 | -26.0K | 20.1K | -56% | -$3.59M |
| D | 2021-08-06 | 2021-08-04 | NTLA | Intellia Therapeutics, Inc. | Sepp-Lorenzino Laura | EVP, CSO | M - OptEx | $13.40 | +26.0K | 28.4K | +1,087% | +$348.4K |
Purchase Sale Sale after option exercise All abbreviations